Double-blind, placebo-controlled trial of continuous oral pamidhonate in rheumatoid arthritis: Effects on bone mass after 1 year

Continuous oral pamidronate (APD), 1000 mg/day, was administered to 14 patients with rheumatoid arthritis. A control group of 13 patients with similar conditions received placebo under a double blind randomized study design. Periarticular erosion scores were significantly higher in the control group after 12 months treatment. This was attributed to a deterioration in this group rather than to an improvement in the APD treated one. By contrast, intraarticular narrowing score was not influenced by APD. Tolerance to oral APD was acceptable in all patients.

show abstract

Double Blind Radiological Assessment of Continuous Oral Pamidronic Acid in Patients with Rheumatoid Arthritis

Maccagno

Digiorgio

Roldán

et al. 1994

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Double-blind, placebo-controlled trial of continuous oral pamidhonate in rheumatoid arthritis: Effects on bone mass after 1 year

Cited by 1 publication

References 0 publications

Double Blind Radiological Assessment of Continuous Oral Pamidronic Acid in Patients with Rheumatoid Arthritis

Double Blind Radiological Assessment of Continuous Oral Pamidronic Acid in Patients with Rheumatoid Arthritis

Contact Info

Product

Resources

About